What is core patent covering Cefoperazone/Sulbactam?

Introduction to Cefoperazone/Sulbactam 
Cefoperazone/sulbactam is a well-established antibiotic combination widely used in clinical practice to fight moderate to severe bacterial infections, particularly those caused by multidrug-resistant gram-negative organisms. This combination strategically pairs a third-generation cephalosporin, cefoperazone, with a β-lactamase inhibitor, sulbactam, to overcome several resistance mechanisms that compromise the efficacy of β-lactam antibiotics. The scientific literature and clinical reports demonstrate that this combination is pivotal in treating intra-abdominal, respiratory, and urinary tract infections, among others, while its advanced formulation has spurred robust patent protection to secure its market exclusivity and improved clinical performance.

Overview of Cefoperazone 
Cefoperazone is classified as a third-generation cephalosporin distinguished by its broad-spectrum activity against both gram-positive and gram-negative bacteria. Its mechanism of action involves interfering with the bacterial cell wall synthesis, ultimately leading to cell lysis and death. Owing to its relatively long elimination half-life (approximately 2 hours), cefoperazone can be administered twice daily, which contributes to its practicality in hospital settings. Crucially, cefoperazone exhibits significant activity against pathogens that display resistance to other cephalosporins. Its inclusion in clinical studies has underscored its efficacy even in the presence of β-lactamases due to its synergistic action when combined with inhibitors like sulbactam.

Overview of Sulbactam 
Sulbactam is a β-lactamase inhibitor that, on its own, has limited antibacterial activity but plays a critical role in enhancing the efficacy of partner antibiotics like cefoperazone. By inhibiting the enzymes (β-lactamases) produced by resistant strains of bacteria, sulbactam prevents the degradation of cefoperazone, thus preserving its antibacterial activity. This synergistic effect is particularly important in the context of infections caused by extended-spectrum β-lactamase (ESBL) producing organisms, where monotherapy with cefoperazone might otherwise be compromised.

Combination Rationale 
The rationale behind combining cefoperazone with sulbactam is grounded in optimizing the antibiotic’s spectrum of activity and countering resistance. While cefoperazone disrupts the bacterial cell wall, sulbactam serves as a protective agent that ensures cefoperazone remains active in the presence of β-lactamase enzymes. This dual mechanism has been particularly beneficial against strains of Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii, where monotherapy might be inadequate. Additionally, the combination is versatile in dosing regimens—for instance, the 2:1 formulation (cefoperazone:sulbactam) is commonly used clinically, though alternative ratios (e.g., 1:1, 3:1) have been investigated for optimizing clinical outcomes. The enhanced antibacterial activity and improved clinical safety profile rendered by this combination have contributed to its adoption as a first-line empirical therapy in severe infections, thereby necessitating robust patent protection for its innovative formulation and manufacturing process.

Patent Landscape of Cefoperazone/Sulbactam 
The patent landscape surrounding cefoperazone/sulbactam is complex and multifaceted, reflecting both the longstanding clinical use of the combination and ongoing innovations designed to improve its safety, stability, and efficacy. Given the critical role this combination plays in addressing multidrug-resistant infections, patents covering its formulation, mode of preparation, and specific therapeutic benefits are considered core to a company’s intellectual property portfolio.

Core Patent Identification 
A core patent in the context of cefoperazone/sulbactam typically focuses on the pharmaceutical composition that not only combines these two active substances in a specific, controlled ratio but also confers enhanced clinical advantages such as improved dissolution rates, reduced adverse reactions (e.g., allergic responses), and superior stability. Among the various patents that have been issued or are pending in this domain, one of the most prominent is the patent described in reference. This patent, titled “Injection Cefoperazone Sodium and Sulbactam Sodium Pharmaceutical Composition for Reducing Allergic Reaction,” outlines a specialized injectable formulation designed to mitigate allergic reactions while maintaining high dissolution speed and stable product quality. 

Additionally, another relevant patent is detailed in reference, which discloses a combination containing sulbactam (or its pharmaceutically acceptable salt) alongside other β-lactamase inhibitors and antibiotics, including cefoperazone, for use in treating various bacterial infections, particularly those caused by pathogens such as Acinetobacter spp. and Enterobacteriaceae. Although it covers a broader spectrum by including multiple active components, it reinforces the importance of the cefoperazone/sulbactam combination in treating significant infections and underscores the protective measures taken via patent claims to secure the formulation’s usage. 

These patents form the core of the intellectual property protecting the cefoperazone/sulbactam combination by safeguarding novel formulations that improve clinical outcomes and reduce side effects. The emphasis on enhancing safety—specifically by reducing allergic reactions—and ensuring rapid, complete dissolution are central claims that differentiate these formulations from prior art, thereby constituting the “core” patents covering this combination. The strategic focus on these aspects not only highlights the scientific and clinical innovations but also strengthens the market positioning of these products against generic competitors.

Patent Claims and Coverage 
The claims within the core patents for cefoperazone/sulbactam typically include a range of protective measures that encompass: 

1. Composition Claims: 
The patents claim the pharmaceutical composition comprising cefoperazone sodium and sulbactam sodium in a defined ratio (often 2:1, but with alternative ratios possible) that provides optimal antibacterial efficacy. These claims extend to the specific physical and chemical properties of the composition, including aspects such as crystal form, dissolution rate, and stability profiles. The improved dissolution speed and reduced impurities are highlighted as essential features of the patented formulation. 

2. Formulation and Pharmaceutical Processing Claims: 
Beyond the mere combination of the two active substances, the patents claim the unique manufacturing methods that ensure stable product quality and low adverse reaction profiles. The processing techniques that lead to quick dissolution and minimal content of related substances are explicitly reserved under these claims, thereby protecting the commercialization-ready product. Often, these methods involve carefully controlled conditions that optimize the interactions between cefoperazone and sulbactam, which is a critical factor in reducing the incidence of allergic reactions. 

3. Method of Use Claims: 
The patents further claim the use of this specific formulation in treating a wide range of bacterial infections, emphasizing its efficacy against pathogens known to produce β-lactamases. These method claims cover the dosing regimens, routes of administration (e.g., intravenous injection), and the specific therapeutic contexts in which the composition is superior to alternative therapies. This not only protects the formulation itself but also the clinical protocols that benefit from its enhanced performance. 

4. Safety Profile Claims: 
A distinguishing factor of the core patents is the explicit assertion of a reduced risk of adverse immune reactions. For example, the patent underlines that the injectable formulation has a lower potential for inducing allergic reactions compared to earlier compositions. This claim is supported by data and experimental findings, which are incorporated into the patent documentation to substantiate the safety advantages of the proprietary formulation. 

The comprehensive nature of these claims ensures that the core patent provides broad protection for the innovative features of the cefoperazone/sulbactam combination. The coverage not only protects the basic chemical and formulation aspects of the combination but also extends to the methods by which the composition achieves its improved clinical efficacy and safety profile. This robust claim structure is designed to block competitors from devising similar compositions that could undermine the proprietary position in the market.

Patent Status and Duration 
The core patents covering cefoperazone/sulbactam formulations, such as the patent described, are generally granted as part of a well-structured intellectual property strategy focused on securing a competitive advantage for a defined period. Although the exact filing dates and expiration dates are not always publicly disclosed in detail within the available references, it is standard practice that patents in pharmaceuticals enjoy a term of approximately 20 years from the filing date. This period may be subject to extensions under specific regulatory provisions, such as patent term restoration or supplementary protection certificates (SPC), particularly if the product undergoes delays during the regulatory approval process. 

The duration of these patents is critical in maintaining market exclusivity. During this period, the patent holder can prevent generic manufacturers from entering the market with equivalent formulations, thereby preserving both the innovation’s commercial value and its competitive advantage. As the core patents are a cornerstone for sustained revenue, companies often aggressively defend these patents through legal channels to ward off infringement and to protect the unique clinical benefits established by the proprietary formulation of cefoperazone/sulbactam. 

The high dissolution speed, stable quality, and reduced allergic reaction features claimed in these patents are continuously monitored and validated during the product lifecycle, further reinforcing the scope and enforceability of the patents. In summary, the core patents are positioned not only as a scientific and technological asset but also as an essential legal instrument that underpins the strategic market exclusivity of cefoperazone/sulbactam-based products.

Implications of the Core Patent 
The core patent covering cefoperazone/sulbactam carries profound implications for the pharmaceutical market, influencing market dynamics, competitive strategies, and regulatory considerations. The protection afforded by the core patent supports both the clinical promise of the product and the commercial interests of the innovator.

Market Impact 
From a market perspective, the core patent provides significant advantages: 

1. Market Exclusivity and Pricing Strategy: 
With robust patent protection in place, the innovator can secure a period of market exclusivity during which it can command premium pricing based on the superior clinical performance and safety benefits of its formulation. The improved dissolution rates and reduced adverse effects, such as lower incidences of allergic reactions, contribute to establishing a high-value brand image. This exclusivity is particularly important in the context of severe infections where rapid and reliable treatment is paramount. 

2. Enhanced Clinical Adoption: 
The clinical advantages covered by the patents reinforce the rationale for early adoption of cefoperazone/sulbactam in the treatment of multidrug-resistant infections. Hospitals and clinical practitioners benefit from a formulation that not only exhibits strong antibacterial activity but also minimizes the risk of complications, thereby improving patient outcomes. Consequently, healthcare providers are more likely to favor a patented formulation over alternative therapies that lack robust supporting clinical data and legal protection. 

3. Investment and Commercial Viability: 
Securing a core patent boosts the confidence of investors and stakeholders by ensuring that the research and development investments yield a protected product in the market. The long-term exclusivity provided by the patent helps to justify the cost-intensive clinical trials and manufacturing processes. In turn, this encourages further investment in enhancing existing formulations and exploring adjacent therapeutic areas within the same antibiotic class.

Competitive Landscape 
The competitive landscape in the antibiotic market is rapidly evolving, especially in the realm of β-lactam/β-lactamase inhibitor combinations. The core patent plays a crucial role in defining this landscape: 

1. Barrier to Generic Competition: 
The extensive claims and detailed coverage of the core patent create a formidable barrier for generic manufacturers, who must either wait for the patent expiry or invest significantly in developing alternative formulations that do not infringe on the proprietary claims. This helps sustain the market share of the innovator’s product for the duration of the protection period. 

2. Encouragement of Innovation: 
While the core patent limits direct competition from generic formulations, it also stimulates ongoing innovation. Competitors are forced to either develop novel combinations or improve upon the existing ones through alternative methods of formulation, dosing regimens, or delivery systems. This dynamic not only encourages the advancement of antibiotic therapy for resistant infections but may also lead to supplemental patents or second-generation products that extend the lifecycle of the original innovation. 

3. Strategic Partnerships and Licensing: 
The firm holding the core patent often enters into strategic partnerships or licensing agreements with other pharmaceutical companies to commercialize the product in broader markets or to integrate additional proprietary technologies. Such collaborations can also include co-development of complementary formulations or extended-release versions that are tailored to specific clinical needs, further enhancing the overall product portfolio.

Legal and Regulatory Considerations 
The core patent’s influence extends into the legal and regulatory arena, impacting both the internal strategies of the innovator and the broader framework of antibiotic regulation: 

1. Regulatory Approval and Pharmacovigilance: 
The claims made in the core patent are supported by rigorous clinical data that demonstrate the product’s safety and efficacy. This robust data package is critical during the regulatory approval process, helping to streamline the review of the product and often resulting in a favorable risk–benefit assessment by regulatory agencies. The quality control measures and process optimizations included in the patent claims also facilitate ongoing pharmacovigilance post-approval, ensuring that the marketed product continues to meet high safety standards. 

2. Intellectual Property Enforcement: 
The broad and well-crafted claims of the core patent form the basis for defending the product against infringement. Patent litigation can be an important tool in deterring competitive entry and is particularly significant in markets where generic substitution may threaten the commercial viability of the innovator’s product. In cases where competitors challenge the validity or scope of the patent claims, legal proceedings help clarify the boundaries of the intellectual property, ensuring continued market protection. 

3. Impact on Reimbursement and Health Policy: 
A patented product with validated safety and efficacy often enjoys a privileged position in reimbursement negotiations with payers, including government health agencies and private insurance companies. The documented clinical benefits—such as a reduced rate of allergic reactions and improved dissolution performance—support pricing and reimbursement strategies that can offset the higher cost of the patented product compared to generics. This, in turn, has implications for health policy and access, particularly in countries where antibiotic stewardship is a critical concern.

Future Directions and Research 
Looking ahead, the patent protection for cefoperazone/sulbactam not only secures the product’s current market position but also sets the stage for future innovations. The core patent underpins ongoing research aimed at further enhancing the therapeutic profile of this combination and prolonging its commercial exclusivity in the face of inevitable generic competition.

Potential for New Formulations 
Innovation in drug delivery and formulation is a continuous process. With the foundational technology secured by the core patent, there is significant potential for developing new formulations that can address unmet clinical needs. Future research directions may include: 

1. Alternative Dosing Ratios: 
Investigations into different ratios of cefoperazone to sulbactam (for example, 1:1, 3:1) are ongoing, as these studies have shown promise by optimizing antibacterial efficacy while minimizing side effects. The ability to fine-tune the balance of cefoperazone and sulbactam can lead to supplemental patents that further extend the period of market exclusivity. 

2. Extended-Release and Novel Delivery Systems: 
Formulations that offer extended-release profiles or enable alternative routes of administration (e.g., intramuscular injection, novel oral formulations) can provide significant clinical advantages. Such innovations aim to improve patient compliance, reduce dosing frequency, and broaden the therapeutic utility of the combination. These innovations are likely to be protected by additional patents that build upon the core technology. 

3. Improved Safety and Stability Profiles: 
Research continues to focus on enhancing the chemical stability and reducing the adverse reaction rates of the composition. Optimized manufacturing processes and novel excipient selections lay the groundwork for new intellectual property that addresses longstanding issues such as stability under varying storage conditions and the minimization of impurities that could lead to allergic responses.

Patent Expiry and Generic Competition 
While the current core patents provide extensive market protection, the eventual expiration of these patents will open the gateway for generic competition. The implications of patent expiry include: 

1. Market Transition to Generics: 
Upon the expiry of the core patent, generic manufacturers will have the opportunity to produce and market equivalent formulations of cefoperazone/sulbactam. This transition typically results in a significant reduction in drug prices, thus enhancing patient access. However, the original innovator may continue to maintain a competitive edge through the development of advanced formulations or by leveraging additional patents covering peripheral innovations. 

2. Lifecycle Management Strategies: 
Innovators often undertake lifecycle management strategies—such as the filing of supplemental patents covering new formulations, methods of administration, or manufacturing processes—to extend the commercial life of a product beyond the expiration of the core patent. This approach not only delays generic competition but also reinforces the brand’s market identity as the provider of the most advanced and safest formulation. 

3. Health Policy and Reimbursement Considerations: 
As generic versions of cefoperazone/sulbactam enter the market, regulatory bodies and payers may re-evaluate reimbursement policies to ensure that cost savings are passed on to patients without compromising therapeutic efficacy. The original patented formulation, with its documented superior safety profile and proven clinical benefits, may continue to be favored in certain high-risk patient populations even after generic entry.

Ongoing Research and Development 
The future of cefoperazone/sulbactam is intricately linked to ongoing research and development efforts that focus on addressing the ever-changing landscape of bacterial resistance and clinical demands. Key research areas include: 

1. Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling: 
Advanced modeling and simulation techniques are being used to optimize dosing regimens and to better understand the in vivo dynamics of cefoperazone/sulbactam. Such studies are crucial for tailoring therapy to individual patient needs, thereby enhancing clinical outcomes. These studies also generate valuable data that can support future patent filings and regulatory submissions. 

2. Clinical Efficacy Studies: 
Extensive clinical investigations, including retrospective and prospective cohort studies, continue to evaluate the efficacy, safety, and potential adverse effects (such as coagulation disorders or allergic reactions) of cefoperazone/sulbactam. These studies not only inform clinical practice but also provide the scientific basis for further formulation improvements and supplementary patent applications. 

3. Expansion of Therapeutic Indications: 
Ongoing research is exploring the potential of cefoperazone/sulbactam in treating a broader spectrum of infections, including those caused by emerging multidrug-resistant pathogens. The ability to extend the therapeutic indications of the composition can lead to new method-of-use patents, thereby enhancing the overall value proposition of the product. 

4. Collaborative Research and Strategic Alliances: 
Collaboration between academic institutions, biotechnology companies, and large pharmaceutical firms is driving innovation in the antibiotic space. Such strategic alliances often result in co-development agreements and shared patents, which can further consolidate the market presence of cefoperazone/sulbactam. These collaborations not only foster innovation but also ensure a continuous pipeline of advancements that support the clinical and commercial viability of the formulation.

Conclusion 
In a general sense, the core patent covering cefoperazone/sulbactam is a critical piece of intellectual property that protects an innovative pharmaceutical composition designed to maximize antibacterial efficacy against multidrug-resistant organisms while simultaneously reducing adverse reactions—chiefly allergic responses. Specifically, the core patent—as exemplified by the one described—claims a unique injectable formulation of cefoperazone sodium and sulbactam sodium. This patent encompasses not only the precise chemical composition but also the advanced manufacturing processes that yield a product with high dissolution speed, stable quality, and a favorable safety profile. Complementary patents further reinforce the strategic protection of this combination by covering its therapeutic use in treating infections caused by resistant pathogens like Acinetobacter spp. and Enterobacteriaceae. 

From a market perspective, the core patent plays an essential role in extending the innovator’s market exclusivity, supporting premium pricing, and fostering early clinical adoption by ensuring superior efficacy and safety. It creates robust barriers against generic competition and, through ongoing research and lifecycle management strategies, paves the way for continuous innovation in formulation and dosing strategies. Legally and regulatory, the core patent facilitates a smooth pathway to product registration, guides post-marketing surveillance in pharmacovigilance, and supports favorable reimbursement negotiations with healthcare payers. 

Looking ahead, the innovative edge secured by the core patent is likely to be maintained and extended through further research and development. New formulations, alternative dosing ratios, and novel delivery systems promise to not only enhance the already proven clinical benefits of cefoperazone/sulbactam but also to extend its patent life via supplemental intellectual property protections. Ultimately, while the eventual expiration of the core patent will invite generic competition and potentially lower drug prices, the continued focus on innovation and improved clinical outcomes will ensure that the advanced formulations remain a benchmark in the treatment of serious infections. 

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.